Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, European University of Lefke, Mersin 10, Lefke, Northern Cyprus, Turkey.
Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Eastern Mediterranean University, Mersin 10, Famagusta, Northern Cyprus, Turkey.
Ir J Med Sci. 2023 Dec;192(6):2937-2947. doi: 10.1007/s11845-023-03333-6. Epub 2023 Mar 10.
Currently, there is no definitive cure for fibromyalgia. Instead, treatments focus of reducing symptoms and disability.
This randomized controlled study aimed to evaluate the effectiveness of perceptive rehabilitation and soft tissue and joint mobilization on the severity of symptoms and disability in fibromyalgia compared with a control group.
A total of 55 fibromyalgia patients were randomized into three groups: perceptive rehabilitation, mobilization, and control. The impact of fibromyalgia was evaluated using the Revised Fibromyalgia Impact Questionnaire (FIQR; primary outcome). Pain intensity, fatigue severity, depression, and sleep quality were secondary outcome measures. Data were collected at baseline (T0), the end of treatment (8 weeks; T1), and the end of 3 months (T2).
Statistically significant differences were found in between-groups comparisons at T1 for primary and secondary outcome measurements (p < .05), except for sleep quality. Both the perceptive rehabilitation and mobilization groups had statistically significant differences at T1 over the control group (p < .05). Between-group pairwise comparisons showed statistically significant differences between the perceptive and control groups for all outcome measures at T1 (p < .05). Similarly, statistically significant differences existed between the mobilization and control groups for all outcome measures at T1 (p < .05), except the FIQR overall impact scores. All other variables except depression were statistically similar between groups at T2.
This study shows that perceptive rehabilitation and mobilization therapy are similarly effective in improving fibromyalgia symptoms and disability, but the effects disappear within 3 months. Further research is needed to understand how the improvements could be maintained longer.
Clinical Trial Registration number, ClinicalTrials.gov Identifier: NCT03705910.
目前，尚无针对纤维肌痛的确切疗法。相反，治疗重点是减轻症状和残疾。
本随机对照研究旨在评估感知康复以及软组织和关节松动术与对照组相比，对纤维肌痛症状和残疾严重程度的影响。
共 55 例纤维肌痛患者随机分为感知康复组、松动组和对照组。采用修订版纤维肌痛影响问卷（FIQR；主要结局指标）评估纤维肌痛的影响。疼痛强度、疲劳严重程度、抑郁和睡眠质量是次要结局指标。数据在基线（T0）、治疗结束时（8 周；T1）和治疗结束后 3 个月（T2）收集。
T1 时，主要和次要结局指标的组间比较存在统计学差异（p<0.05），除睡眠质量外。感知康复组和松动组在 T1 时与对照组相比均有统计学差异（p<0.05）。组间两两比较显示，T1 时感知组与对照组在所有结局指标上差异均有统计学意义（p<0.05）。同样，T1 时松动组与对照组在所有结局指标上差异均有统计学意义（p<0.05），除 FIQR 总影响评分外。T2 时，除抑郁外，所有其他变量在组间均无统计学差异。
本研究表明，感知康复和松动治疗在改善纤维肌痛症状和残疾方面同样有效，但效果在 3 个月内消失。需要进一步研究以了解如何能使改善更持久。
临床试验注册号，ClinicalTrials.gov 标识符：NCT03705910。
